The SEAD™ has the potential of becoming a strong and attractive choice
of therapy in the worldwide GEA market through its simplicity,
cost-effectiveness and new and innovative yet gentle “substance-based Ablation” technology.
OM-80 is based on the proprietary IUB™ platform and is currently in concept development.